Meeting
2019 ASCO Annual Meeting
Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.
Authors
Catherine Handy Marshall
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Catherine Handy Marshall , Wei Fu , Hao Wang , Bruce J. Trock , Mario A. Eisenberger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5016)
DOI
10.1200/JCO.2019.37.15_suppl.5016
Abstract #
5016
Poster Bd #
128
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
First Author: Heba Mohamed
Poster
2020 Genitourinary Cancers Symposium
A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC).
First Author: Irbaz Bin Riaz
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay